Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1997 Apr;52(4):342–347. doi: 10.1136/thx.52.4.342

Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005

B Dahlen, M Kumlin, E Ihre, O Zetterstrom, S E Dahlen
PMCID: PMC1758539  PMID: 9196517

Abstract

BACKGROUND: Leukotriene receptor antagonists significantly blunt allergen-induced bronchoconstriction in asthmatic subjects. Inhibitors of leukotriene synthesis should theoretically provide similar protection, but conflicting results have been obtained when synthesis inhibitors have been tested in allergen challenge. BAYx 1005, a new inhibitor of leukotriene synthesis, was therefore evaluated in an allergen bronchoprovocation study. METHODS: Ten men with mild allergic asthma and bronchial hyperresponsiveness to histamine were recruited. On two different occasions each subject inhaled a single dose of allergen, previously determined to cause at least a 20% fall in forced expiratory volume in one second (FEV1) four hours after ingestion of 750 mg BAYx 1005 or placebo in a double blind crossover design. Urinary excretion of leukotriene E4 was measured before and during the challenges. RESULTS: The mean (SE) maximal fall in FEV1 was 7.1 (1.7)% after BAYx 1005 and 21.0 (3.0)% after placebo (p < 0.001). The mean difference between treatments was 13.9 (95% CI 7.0 to 20.8) for the maximal fall in FEV1. All subjects were protected by BAYx 1005, the mean inhibition of the fall in FEV1 being 70.0 (7.0)%. The mean area under the curve (AUC) for urinary excretion of leukotriene E4 in the first two hours after the challenge was 1.7 (0.9) after placebo and 0.4 (0.6) after BAYx 1005 (difference = 1.3 (95% CI-0.1 to 2.7); p < 0.05). CONCLUSIONS: These results indicate that BAYx 1005 is a potent inhibitor of allergen-provoked leukotriene synthesis in asthmatic subjects and lend further support to the suggestion that leukotrienes are important mediators of allergen-induced bronchoconstriction. 




Full Text

The Full Text of this article is available as a PDF (157.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Christie P. E., Smith C. M., Lee T. H. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis. 1991 Oct;144(4):957–958. doi: 10.1164/ajrccm/144.4.957. [DOI] [PubMed] [Google Scholar]
  2. Chung K. F. Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur Respir J. 1995 Jul;8(7):1203–1213. doi: 10.1183/09031936.95.08071203. [DOI] [PubMed] [Google Scholar]
  3. Dahlén B., Kumlin M., Margolskee D. J., Larsson C., Blomqvist H., Williams V. C., Zetterström O., Dahlén S. E. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J. 1993 Jul;6(7):1018–1026. [PubMed] [Google Scholar]
  4. Dixon R. A., Diehl R. E., Opas E., Rands E., Vickers P. J., Evans J. F., Gillard J. W., Miller D. K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature. 1990 Jan 18;343(6255):282–284. doi: 10.1038/343282a0. [DOI] [PubMed] [Google Scholar]
  5. Finnerty J. P., Wood-Baker R., Thomson H., Holgate S. T. Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):746–749. doi: 10.1164/ajrccm/145.4_Pt_1.746. [DOI] [PubMed] [Google Scholar]
  6. Friedman B. S., Bel E. H., Buntinx A., Tanaka W., Han Y. H., Shingo S., Spector R., Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis. 1993 Apr;147(4):839–844. doi: 10.1164/ajrccm/147.4.839. [DOI] [PubMed] [Google Scholar]
  7. Gardiner P. J., Cuthbert N. J., Francis H. P., Fitzgerald M. F., Thompson A. M., Carpenter T. G., Patel U. P., Newton B. B., Mohrs K., Müller-Peddinghaus R. Inhibition of antigen-induced contraction of guinea-pig airways by a leukotriene synthesis inhibitor, BAY x1005. Eur J Pharmacol. 1994 Jun 2;258(1-2):95–102. doi: 10.1016/0014-2999(94)90061-2. [DOI] [PubMed] [Google Scholar]
  8. Gorenne I., Labat C., Gascard J. P., Norel X., Müller-Peddinghaus R., Mohrs K. H., Taylor W. A., Gardiner P. J., Brink C. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. J Pharmacol Exp Ther. 1994 Feb;268(2):868–872. [PubMed] [Google Scholar]
  9. Hamilton A. L., Watson R. M., Wyile G., O'Byrne P. M. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax. 1997 Apr;52(4):348–354. doi: 10.1136/thx.52.4.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hatzelmann A., Fruchtmann R., Mohrs K. H., Raddatz S., Müller-Peddinghaus R. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Biochem Pharmacol. 1993 Jan 7;45(1):101–111. doi: 10.1016/0006-2952(93)90382-7. [DOI] [PubMed] [Google Scholar]
  11. Hills M., Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979 Jul;8(1):7–20. doi: 10.1111/j.1365-2125.1979.tb05903.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jonsson E. W., Dahlén S. E. Interactions between leukotrienes and histamine in the anaphylactic contraction of guinea pig lung parenchyma. J Pharmacol Exp Ther. 1994 Nov;271(2):615–623. [PubMed] [Google Scholar]
  13. Kumlin M., Dahlén B., Björck T., Zetterström O., Granström E., Dahlén S. E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis. 1992 Jul;146(1):96–103. doi: 10.1164/ajrccm/146.1.96. [DOI] [PubMed] [Google Scholar]
  14. Kumlin M., Dahlén S. E. Characteristics of formation and further metabolism of leukotrienes in the chopped human lung. Biochim Biophys Acta. 1990 May 22;1044(2):201–210. doi: 10.1016/0005-2760(90)90304-g. [DOI] [PubMed] [Google Scholar]
  15. Kumlin M., Stensvad F., Larsson L., Dahlén B., Dahlén S. E. Validation and application of a new simple strategy for measurements of urinary leukotriene E4 in humans. Clin Exp Allergy. 1995 May;25(5):467–479. doi: 10.1111/j.1365-2222.1995.tb01079.x. [DOI] [PubMed] [Google Scholar]
  16. Manning P. J., Rokach J., Malo J. L., Ethier D., Cartier A., Girard Y., Charleson S., O'Byrne P. M. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol. 1990 Aug;86(2):211–220. doi: 10.1016/s0091-6749(05)80068-5. [DOI] [PubMed] [Google Scholar]
  17. Manning P. J., Watson R. M., Margolskee D. J., Williams V. C., Schwartz J. I., O'Byrne P. M. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990 Dec 20;323(25):1736–1739. doi: 10.1056/NEJM199012203232504. [DOI] [PubMed] [Google Scholar]
  18. Nasser S. M., Bell G. S., Hawksworth R. J., Spruce K. E., MacMillan R., Williams A. J., Lee T. H., Arm J. P. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax. 1994 Aug;49(8):743–748. doi: 10.1136/thx.49.8.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nieminen M. M., Lahdensuo A., Kellomaeki L., Karvonen J., Muittari A. Methacholine bronchial challenge using a dosimeter with controlled tidal breathing. Thorax. 1988 Nov;43(11):896–900. doi: 10.1136/thx.43.11.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rasmussen J. B., Eriksson L. O., Margolskee D. J., Tagari P., Williams V. C., Andersson K. E. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992 Aug;90(2):193–201. doi: 10.1016/0091-6749(92)90071-9. [DOI] [PubMed] [Google Scholar]
  21. Robuschi M., Riva E., Fuccella L. M., Vida E., Barnabe R., Rossi M., Gambaro G., Spagnotto S., Bianco S. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis. 1992 Jun;145(6):1285–1288. doi: 10.1164/ajrccm/145.6.1285. [DOI] [PubMed] [Google Scholar]
  22. Sladek K., Dworski R., Fitzgerald G. A., Buitkus K. L., Block F. J., Marney S. R., Jr, Sheller J. R. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans. Effect of indomethacin. Am Rev Respir Dis. 1990 Jun;141(6):1441–1445. doi: 10.1164/ajrccm/141.6.1441. [DOI] [PubMed] [Google Scholar]
  23. Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES